CIBC started coverage on shares of Outlook Therapeutics (NASDAQ:OTLK) in a report published on Thursday, FirstToMarketsRatingsTable reports. The firm issued an outperform rating and a $12.00 target price on the stock.
Several other research firms also recently commented on OTLK. ValuEngine upgraded shares of Outlook Therapeutics from a hold rating to a buy rating in a research report on Wednesday, March 20th. Oppenheimer began coverage on shares of Outlook Therapeutics in a research note on Thursday. They issued an outperform rating and a $12.00 price objective on the stock. Finally, Ascendiant Capital Markets began coverage on shares of Outlook Therapeutics in a research note on Monday, April 22nd. They issued a buy rating and a $4.00 price objective on the stock.
OTLK stock traded up $0.88 on Thursday, hitting $2.41. The company’s stock had a trading volume of 58,265,350 shares, compared to its average volume of 991,696. Outlook Therapeutics has a 1 year low of $0.85 and a 1 year high of $10.96.
Outlook Therapeutics (NASDAQ:OTLK) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.08. The business had revenue of $0.64 million during the quarter.
An institutional investor recently bought a new position in Outlook Therapeutics stock. Renaissance Technologies LLC purchased a new position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 11,166 shares of the company’s stock, valued at approximately $83,000. Renaissance Technologies LLC owned approximately 0.10% of Outlook Therapeutics at the end of the most recent quarter. 4.60% of the stock is currently owned by institutional investors and hedge funds.
Outlook Therapeutics Company Profile
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
Featured Story: Return On Assets
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.